Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib.

Niinivirta, Marjut; Enblad, Gunilla; Lindskog, Cecilia; Pontén, Fredrik; Dragomir, Anca; Ullenhag, Gustav J

Niinivirta, Marjut; Enblad, Gunilla; Lindskog, Cecilia; Pontén, Fredrik; Dragomir, Anca; Ullenhag, Gustav J.

Afiliação

Niinivirta M; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Enblad G; Department of Oncology, Uppsala University Hospital, Entrance 78, 751 85 Uppsala, Sweden.
Lindskog C; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Pontén F; Department of Oncology, Uppsala University Hospital, Entrance 78, 751 85 Uppsala, Sweden.
Dragomir A; Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, Dag Hammarskjölds väg 20, 751 85 Uppsala, Sweden.
Ullenhag GJ; Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, Dag Hammarskjölds väg 20, 751 85 Uppsala, Sweden.

J Cancer ; 10(14): 3224-3231, 2019.

Article em En | MEDLINE | ID: mdl-31289593

Palavras-chave

PKLR; predictive marker; renal cancer; tyrosine kinase inhibitor

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suécia País de publicação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google